Covering the Endocrine Society's Annual Meeting—Resources for Journalists

The Endocrine Society's annual meeting is a unique opportunity for journalists to learn about the latest research in fields as diverse as obesity, diabetes, endocrine-disrupting chemicals, growth hormones, thyroid conditions, reproductive health, endocrine cancers, and much more. Thousands of endocrinologists from around the globe attend the meeting each year to share the latest advances in research and clinical practice.

Covering ENDO 2019

During ENDO 2019, the Society will host press conferences and provide on-site office space for journalists covering the annual meeting. The meeting will be held at the Ernest N. Morial Convention Center in New Orleans, LA, from March 23-26, 2019. Register now to apply for press credentials.

Registering as media does not guarantee approval in receiving a press pass. The Endocrine Society will review the credentials of all reporters seeking to attend ENDO to ensure eligibility requirements are met. Media approved for attendance will receive official notification via email from Endocrine Society staff. Contact media@endocrine.org for additional information.

Journalists can pick up press credentials and other materials in the on-site newsroom, room 348-349. The newsroom is open from 7:30 AM to 5 PM Central on March 23-25 and from 7:30 AM to 2 PM on March 26.

News Conferences

Saturday, March 23

Diabetes (8:30 a.m. CDT): The Society is unveiling its new Clinical Practice Guideline on treating older adults with diabetes. Researchers will also discuss how many older adults with type 1 diabetes are unaware of when they have low blood sugar, the technical challenges with implementing a new hybrid closed loop insulin pump (the precursor to the artificial pancreas), and how the hemoglobin A1c (HbA1c) test misses many cases of diabetes.

Reproductive Health (11 a.m. CDT): Studies will highlight the correlation between improved PCOS symptoms and healthy gut bacteria, long-term opioid use and hormone deficiencies, how gender-affirming hormone therapy can strengthen brain connections in transgender women, and how repeat miscarriages may be caused by sperm DNA damage.

Sunday, March 24

Obesity (10 a.m. CDT): This press conference will examine the hormone oxytocin and its ability to weaken the brain’s reward signals for food, a hormone released from fat tissue and how it may play a role in obesity-related asthma, exposure to HIV before birth and its link to obesity later in life, and why teens who sit for hours in front of the TV while eating unhealthy snacks are at increased risk for heart disease and diabetes.

EDCs (11:30 a.m. CDT): The EDC experts in this news conference will present research on chemicals in household dust and fat cell development, and how exposure to the widely used chemical bisphenol A (BPA) during pregnancy can alter circadian rhythms.

Monday, March 25

Aging (8 a.m. CDT): The Society is debuting a new Clinical Practice Guideline for treating osteoporosis in postmenopausal women. Researchers will also cover older men with higher levels of sex hormones and why they have a lower biological age, how changing when you eat may prevent postmenopausal breast cancer, and why walking downhill after meals may have a positive effect on bone health in postmenopausal women.

Emerging Issues in Reproductive Health (10 a.m. CDT): Researchers will explore a second potential male birth control pill, sperm production recovery after performance-enhancing drug abuse, levothyroxine’s ability to improve the chance of live birth in women with thyroid antibodies, and hormone therapy’s effect on brain connections in transgender women.

View recorded ENDO 2018 news conferences on endocrine-disrupting chemicals, reproductive health, diet, obesity, and obesity.

Annual Meeting Embargo Policy

Unless otherwise noted, all abstracts presented at ENDO are embargoed until the date and time of presentation. For oral presentations, the abstracts are embargoed until the session begins. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO.